National Academies Press: OpenBook

CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary (2010)

Chapter: Appendix C: Workshop Attendees

« Previous: Appendix B: Workshop Agenda
Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×

C
Workshop Attendees

Omar Ali

i3 Statprobe


Larry Alphs

Ortho-McNeil Janssen Scientific Affairs, LLC


Mark Bangs

Eli Lilly and Company


Hendricks Brown

University of Miami


Pilar Cazorla


Kathryn Connor

Merck Research Laboratories


Vladimir Coric

Bristol-Myers Squibb


Brenda Crowe

Eli Lilly and Company


Rosina Dixon

Sanofi-Aventis


Sarah DuBrava

Pfizer


Amy Ellis

MedAvante


Reuven Ferziger


Regan Fong

GlaxoSmithKline


Richard Frank

GE Healthcare


Harry Gedney

National Park Service


Alan Gelenberg

Healthcare Technology Systems, Inc.

Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×

Paul Gilbert

MedAvante


Laurence Greenhill


Owen Hagino

Sanofi-Aventis


Richard Hodes

National Institutes of Health


Yiqun Hu

FRI


Joseph Hulihan

Ortho-McNeil Janssen Scientific Affairs


Neely Ivgy-May

Schering Plough Corp.


Thomas Konechnik

Eli Lilly and Company


Stephen H. Koslow

American Foundation for Suicide Prevention


Mary Kujawa

Hoffmann-LaRoche, Inc.


Deborah Lazzaretto

New York State Psychiatric Institute


Susi Lee

Merck & Co., Inc


Anne Libby

University of Colorado at Denver


Alan Lipschitz

GlaxoSmithKline


Clare Makumi

GlaxoSmithKline


Randall Marshall

Sepracor, Inc.


Roger Meyer

Best Practice Project Management, Inc.


Tanya Momtahen

Sanofi-Aventis


Sanjeer Pathak


Jane Pearson

National Institute of Mental Health

David Sheehan

University of South Florida College of Medicine


Peter Sorantin

MedAvante


Susanne Steinberg

Pfizer


Vani Vannappagari

GlaxoSmithKline

Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×

Lingfeng Yang

Wyeth Research


Kseniya Yershova

New York State Psychiatric Institute/Columbia University

Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×

This page intentionally left blank.

Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×
Page 61
Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×
Page 62
Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×
Page 63
Suggested Citation:"Appendix C: Workshop Attendees." Institute of Medicine. 2010. CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12829.
×
Page 64
Next: Appendix D: Biographical Sketches of Invited Speakers »
CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary Get This Book
×
Buy Paperback | $21.00 Buy Ebook | $16.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!